Table 4 Preferred choices of physicians for first systemic chemotherapy, in patients eligible for cisplatin
Usual physician chemotherapy regimen for 1st systemic anti-cancer therapy in patients eligible to cisplatin | Set of Physicians N = 51 |
|---|---|
As neoadjuvant or adjuvant chemotherapya | |
Missing | - |
MVAC | 3 (5.9 %) |
HD-MVAC | 1 (2.0 %) |
GEM-cisplatin | 42 (82.4 %) |
GEM-cisplatin or (HD)-MVAC | 3 (5.9 %) |
Other | 3 (5.9 %) |
As palliative first-line chemotherapy | |
Missing | - |
MVAC | 2 (3.9 %) |
HD-MVAC | - |
GEM-cisplatin | 46 (90.2 %) |
GEM-cisplatin or (HD)-MVAC | 2 (3.9 %) |
Other | 1 (2.0 %) |